Zydus Cadila announces phase III trials of Desidustat to treat non-dialysis anaemia
Zydus Cadila Group Chairman Pankaj R Patel said this innovation has the potential to bring about a paradigm shift in the management of CKD patients with anaemia.
New Delhi: Drug firm Zydus Cadila Wednesday announced phase III clinical trials of Desidustat, an investigational new drug targeted at treating anaemia in non-dialysis dependent chronic kidney disease patients.
"This phase III study will be a multicenter (50-60 sites), randomised, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anaemia in patients with chronic kidney disease (CKD) who are not on dialysis," the company said in a regulatory filing.
Zydus Group Chairman Pankaj R Patel said this innovation has the potential to bring about a paradigm shift in the management of CKD patients with anaemia.
Earlier, Desidustat had met its primary endpoints in phase II clinical study of non-dialysis dependent chronic kidney disease patients suffering from anaemia.
The phase I trials were earlier completed in Australia, the company said.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at email@example.com Contact no. 011-43720751 To know about our editorial team click here